Sysmex (OTCMKTS:SSMXY) Updates FY 2025 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.430-0.430 for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.3 billion.

Sysmex Price Performance

OTCMKTS:SSMXY opened at $8.52 on Friday. The company has a market cap of $5.36 billion, a P/E ratio of 17.75 and a beta of 1.14. The firm’s fifty day moving average price is $9.72 and its two-hundred day moving average price is $11.33. Sysmex has a one year low of $8.15 and a one year high of $19.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 2.49.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. Sysmex had a net margin of 8.86% and a return on equity of 9.32%. The company had revenue of $837.32 million during the quarter, compared to analysts’ expectations of $819.99 million. Equities analysts expect that Sysmex will post 0.57 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.